作者：李星星1，逯金金1，崔晓云1，李冬1，范宗静1，崔杰1，胡继强1，吴旸1，林谦2，李岩1

单位：

1.100078北京市，北京中医药大学东方医院心内科2.100700北京市，北京中医药大学东直门医院心内科

Units：

1.Department of Cardiology, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing 100078, China2.Department of Cardiology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China

关键词：

心房颤动；血栓栓塞性疾病；益气活血中药；新型口服抗凝剂；出血；综述

Keywords：

Atrial fibrillation; Thromboembolic diseases; Traditional Chinese medicine for replenishing Qi andpromoting blood; New oral anticoagulants; Hemorrhage; Review

CLC：

　R 541.75

DOI：

10.12114/j.issn.1008-5971.2022.00.244

Funds：

国家自然科学基金资助项目（81973622）；首都卫生发展科研专项（首发2020-2-4201）；首都卫生发展科研专项（首发2020-2-4203）；北京中医药大学东方医院“1166”人才项目（030903010331）

摘要：

心房颤动是临床常见的心律失常类型，且以非瓣膜性心房颤动（NVAF）为主，其最严重的并发症为血栓栓塞性疾病。新型口服抗凝剂（NOACs）是目前预防心房颤动患者血栓栓塞性疾病的首选药物，但其存在抗凝获益与出血风险的矛盾。目前，采用益气活血中药联合NOACs预防心房颤动患者血栓栓塞性疾病非常普遍，但其安全性的研究报道少见。本文通过分析文献发现，益气活血中药联合NOACs能增强心房颤动患者的抗凝效果，降低血栓栓塞性疾病的发生风险，且可以减少出血风险。

Abstract：

Atrial fibrillation is a common type of arrhythmia in clinic, and non valvular atrial fibrillation (NVAF) is themain type. The most serious complication of NVAF is thromboembolic disease. New oral anticoagulants (NOACs) are currently thefirst choice for the prevention of thromboembolic diseases in patients with atrial fibrillation, but there is a contradiction betweenthe benefits of anticoagulation and the risk of bleeding. At present, it is very common to use traditional Chinese medicine forreplenishing Qi and promoting blood combined with NOACs to prevent thromboembolic diseases in patients with atrial fibrillation,but there are few reports on its safety. Through analyzing the literature, this paper found that traditional Chinese medicinefor replenishing Qi and promoting blood combined with NOACs can enhance the anticoagulation effect of patients with atrialfibrillation, reduce the risk of thromboembolic diseases, and reduce the risk of bleeding.

ReferenceList：